Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6461121 | 0.73 | AHR (0.50) | MAPTKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL21765582 | 0.71 | MAPT (0.54) | MAPTKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL22330404 | 0.64 | MAPT (0.47) | MAPTKMT2AMETDAO | |
| SCHEMBL3599703 | 0.64 | CYP1A2 (0.49) | MAPTKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL29953410 | 0.61 | CYP1A2 (0.46) | MAPTKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL22277965 | 0.60 | KIF11 (0.51) | MAPTKDM4EMEN1KMT2ALMNA | |
| SCHEMBL29399580 | 0.60 | MAPT (0.62) | MAPTKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL15201047 | 0.60 | MAPT (0.62) | MAPTKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL6669696 | 0.60 | KDM4E (0.52) | MAPTKDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL12016684 | 0.60 | MAPT (0.62) | MAPTKDM4EMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9278975-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8946238-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | MAPT 3695/4885KDM4E 2068/4885MEN1 3739/4885 |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | MAPT 3695/4885KDM4E 2068/4885MEN1 3739/4885 |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | MAPT 3695/4885KDM4E 2068/4885MEN1 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.